Skip Navigation


NDT Advance Access originally published online on July 22, 2006
Nephrology Dialysis Transplantation 2006 21(11):3211-3214; doi:10.1093/ndt/gfl356
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/11/3211    most recent
gfl356v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Duranay, M.
Right arrow Articles by Yücel, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duranay, M.
Right arrow Articles by Yücel, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients

Murat Duranay1, Hatice Akay1, Fatma Meriç Yilmaz2, Mehmet Senes2, Nurçin Tekeli1 and Dogan Yücel2

1Dialysis Unit and 2Clinical Biochemistry Laboratory of Ankara Hospital, Ministery of Health, Ankara 06340, Turkey

Correspondence and offprint requests to: Murat Duranay, S.B. Ankara Egitim ve Arastirma Hastanesi Nefroloji Klinigi, 06340 Mamak/Ankara, Turkey. Email: fatmamericyilmaz{at}hotmail.com

Background. Carnitine loss through dialysis membranes is shown to be related to the lack of carnitine in long-term haemodialysis patients. It has been previously reported that haemodialysis patients might have benefited from carnitine supplementation.

Methods. A total of 21 chronic haemodialysis patients maintaining carnitine supplementation and 21 controls (haemodialysis patients not receiving carnitine) were included in the study. L-carnitine was used intravenously three times a week after each haemodialysis session, at a 20 mg/kg dose. C-reactive protien (CRP), lipid profile, transferrin, total protein and albumin levels were determined at baseline after 3 and 6 months of treatment, and compared with the control group.

Results. CRP levels were significantly decreased in carnitine group in contrast to the increase in the control group. Transferrin, total protein and albumin levels and body mass index (BMI) of the patients rose in the carnitine group.

Conclusions. There was a significant benefit of L-carnitine on CRP, transferrin, total protein and albumin levels of the haemodialysis patients.

Keywords: CRP; haemodialysis; inflammation; L-carnitine; nutrition


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.